Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 16/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.66 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.63 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528384 | 0.94 | RXFP1 (0.77) | SGMS2RXFP1 | |
| SCHEMBL17551879 | 0.92 | SGMS2 (0.83) | SGMS2 | |
| SCHEMBL17551875 | 0.87 | SGMS2 (1.00) | SGMS2 | |
| SCHEMBL30543377 | 0.87 | SGMS2 (1.00) | SGMS2 | |
| SCHEMBL31261727 | 0.87 | SGMS2 (1.00) | SGMS2 | |
| SCHEMBL17551870 | 0.86 | SGMS2 (0.83) | SGMS2 | |
| SCHEMBL30322947 | 0.86 | SGMS2 (0.83) | SGMS2 | |
| SCHEMBL22323774 | 0.85 | MEN1 (0.67) | SGMS2MAPK1HSD17B10RXFP1KCNK3 | |
| SCHEMBL30322841 | 0.85 | SGMS2 (1.00) | SGMS2ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL19133749 | 0.85 | SGMS2 (1.00) | SGMS2ALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | SGMS2 459/4885ALDH1A1 646/4885MAPK1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.